Considerations and controversies of pharmacologic management of the pediatric kidney transplant recipient. Issue 1 (19th January 2021)

• Record Type: Journal Article
• Authors: Liverman, Rochelle; Chandran, Mary Moss; Crowther, Barrett
• Other Names: Doligalski Christina Teeter guestEditor.; Bowman Lyndsey J. guestEditor.
• Is Part Of: Pharmacotherapy. Volume 41:Issue 1(2021)
• Page Start: 77
• Page End: 102
• Publication Date: 2021-01-19
• Subjects: clinical pharmacology -- graft rejection -- immunosuppressive agents -- kidney transplantation -- pediatrics -- transplant recipients; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1002/phar.2483
• Languages: English
• ISSNs: 0277-0008

Abstract

Abstract: Pediatric kidney transplantation has experienced considerable growth and improvement in patient and allograft outcomes over the past 20 years, in part due to advancements in immunosuppressive regimens and management. Despite this progress, care for this unique population can be challenging due to limited pediatric transplant data and trials, intricacies related to differences in children and adolescents compared with their adult counterparts, and limitations to long‐term survival facing all solid organ transplant populations. Immunosuppression and infection prevention practices vary from one pediatric transplant center to another and clinical controversies exist surrounding treatment and dosing. This review aims to summarize key aspects of pharmacologic management in this population and present pertinent data that describe the influence of practice to serve as a resource for practitioners caring for this unique specialty patient population. Additionally, this review highlights select controversies that exist within pediatric kidney transplantation.